证券代码：300558 证券简称：贝达药业 公告编号：2025-076 贝达药业股份有限公司 第四届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长丁列明先生召集，会议通知于 2025 年 12 月 8 日以电 话、邮件等形式送达全体董事，董事会会议通知中包括会议的相关材料，同时列 明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 12 月 15 日在公司杭州总部行政大楼十五楼会议室 召开，采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 12 人，实际出席会议人数 12 人。 4、本次董事会由董事长丁列明先生主持，公司董事会秘书吴灵犀先生列席 了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《贝达药业股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 二、董事会会议审议情况 1、会议审议并通过了《关于使用部分闲置募集资金暂时补充流动资金的议 案》 根据《深圳证券交易所 ...

Core Viewpoint - Beida Pharmaceutical Co., Ltd. announced that four of its innovative drugs have been included in the National Medical Insurance Directory for 2025, reflecting the recognition of the company's innovation capabilities and the clinical value of its drugs by the national medical insurance department [1][5]. Group 1: Drug Information - The four drugs included are: 1. **Erlotinib Hydrochloride Tablets** - the first domestically developed EGFR-TKI for lung cancer treatment with independent intellectual property rights [1]. 2. **Ensartinib Capsules** - a new generation ALK inhibitor co-developed with Xcovery [1]. 3. **Befotnib** - a third-generation EGFR-TKI and a national class 1 innovative drug with independent intellectual property rights [2]. 4. **Vorolanib Tablets** - a new multi-target tyrosine kinase inhibitor that can inhibit tumor angiogenesis and is used for treating pathological angiogenesis diseases [2]. Group 2: Impact on Business - Inclusion in the National Medical Insurance Directory is expected to enhance the accessibility of these products and positively impact sales [5]. - The directory will be effective from January 1, 2026, and the immediate impact on the company's operating performance cannot be accurately estimated at this time [5].

Group 1 - Century Huatong plans to change the use of 1.28 million repurchased shares from equity incentive plans to cancellation, reducing total share capital from 7.428 billion to 7.427 billion shares [2] - Wuliangye adjusts its 2025 investment plan, increasing the number of projects from 19 to 22 and changing the investment amount from 2.586 billion to 2.207 billion yuan [3] - Qingyue Technology is under investigation for suspected financial data fraud, with the possibility of forced delisting if found guilty [4] Group 2 - Kang Enbei's chairman and legal representative resigns due to work adjustments, along with another board member [5] - Tianshan Co. expects a tax payment of approximately 61.86 million yuan to impact its 2025 net profit [6] - Muyuan Foods reports a 20.43% year-on-year decline in November sales revenue from live pigs, totaling 9.39 billion yuan [7] Group 3 - GAC Group's November automobile sales decreased by 9.72% year-on-year, with total sales of 1.797 million vehicles [8] - Western Pastoral's fresh milk production in November increased by 6.3% month-on-month but decreased by 6.47% year-on-year [9] - Gemdale Group's November contracted area fell by 58.50% year-on-year, with a total contracted amount of 1.52 billion yuan [10] Group 4 - Zhenghong Technology reports November sales revenue of 4.5196 million yuan from live pigs, with a year-on-year decline of 21.83% [11] - Wens Foodstuff's November chicken sales reached 118 million birds, generating 3.324 billion yuan in revenue [12] - Meilixin's controlling shareholder plans to increase holdings by no less than 50 million yuan [13] Group 5 - Hongcheng Environment's subsidiary wins an 853 million yuan sewage treatment project [14] - Dongzhu Ecology wins a 397 million yuan environmental project [15] - Xindian Software secures a 54 million yuan project for digital community construction [16] Group 6 - China Chemical announces that its nylon new material project has reached full production [17] - Jiaojian Co. is in discussions regarding overdue payments related to financial products, clarifying that it bears no responsibility for these products [18] - Micron Biotech's product is included in the 2025 National Medical Insurance Directory [19] Group 7 - Yitian Intelligent plans to sell 600 smart computing machines for a total of 1.56 billion yuan [20] - First Venture's subsidiary receives an administrative penalty notice from Jiangsu Securities Regulatory Bureau [21] - China Insurance's vice president is under investigation for serious violations [22] Group 8 - Zhixiang Jintai's monoclonal antibody injection is included in the 2025 National Medical Insurance Directory [23] - Haichuang Pharmaceutical's drug is also included in the National Medical Insurance Directory [24] - Yuanli Co. plans to acquire 49% of Clarimex for 25.56 million USD [25] Group 9 - Betta Pharmaceuticals' products are included in the National Medical Insurance Directory [26] - Tianci Materials' controlling shareholder commits to not reducing holdings for six months [27] - Guanglian Aviation's actual controller has had a detention measure lifted [28] Group 10 - Annie Co. announces a share transfer agreement that will make Shengshi Tianan the controlling shareholder [29] - Double Star New Materials notes uncertainty regarding the sustainability of long-term price increases [30] - ST Tianrui terminates plans for a change in control and resumes trading [31] Group 11 - Guao Technology is planning a change in control, leading to a temporary suspension of its stock [32] - Guangqi Technology's subsidiary signs contracts worth 696 million yuan for the production of metamaterials [33] - Shuoshi Biotech's monkeypox virus detection kit is included in the WHO emergency use list [34]

Core Viewpoint - The announcement by Beida Pharmaceutical regarding the inclusion of its products in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 is a significant development for the company and its market positioning [1] Group 1 - Beida Pharmaceutical has announced that its products, including Alectinib Hydrochloride Tablets, Ensartinib Capsules, Bafetinib Mesylate Capsules, and Vorinostat Tablets, have been included in the National Drug List for 2025 [1]

Core Viewpoint - Betta Pharmaceuticals has announced that several of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance the accessibility and market potential of these drugs [1] Group 1 - Betta Pharmaceuticals' products included in the 2025 drug list are: - Hydrochloride Alectinib Tablets (Kaimena) - Hydrochloride Ensartinib Capsules (Beimana) - Mesylate Bafetinib Capsules (Saimena) - Voronib Tablets (Fumeina) [1] - Additionally, the company's Bevacizumab Injection (Beanding) has been included in the National Medical Insurance Category B drug list [1]

Core Viewpoint - The announcement indicates that several products from the company have been included in the National Medical Insurance Drug List for 2025, which is expected to enhance accessibility and positively impact sales, although the exact effect on current performance cannot be accurately estimated [1] Group 1 - The products included are: - Hydrochloride Alectinib Tablets - Hydrochloride Ensartinib Capsules - Mesylate Bafetinib Capsules - Vorinostat Tablets These products will be effective from January 1, 2026, to December 31, 2027 [1] - Additionally, the product Bevacizumab Injection has been included in the National Medical Insurance Category B Drug List [1] Group 2 - Inclusion in the medical insurance list is expected to improve product accessibility [1] - The impact on sales is anticipated to be positive, although the company cannot currently provide an accurate estimate of the effect on its performance [1]

每经AI快讯，12月7日，贝达药业（300558）(300558.SZ)公告称，公司产品盐酸埃克替尼片(凯美纳)、 盐酸恩沙替尼胶囊(贝美纳)、甲磺酸贝福替尼胶囊(赛美纳)以及伏罗尼布片(伏美纳)被纳入《国家基本医 疗保险、生育保险和工伤保险药品目录(2025年)》。此次纳入将提高产品的可及性，对销售产生积极影 响。但对公司当期经营业绩的影响目前无法准确估计。 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-075 贝达药业股份有限公司 关于公司产品纳入《国家医保药品目录》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 恩沙替尼是一种新型强效、高选择性的新一代 ALK 抑制剂，是公司和控股子 公司 Xcovery 共同开发的自主创新药。全球多中心Ⅲ期临床 eXalt 3 研究数据显示 一线治疗经独立评审委员会（IRC）评估 ITT 人群无进展生存期（PFS）为 31.3 个 月，12 个月内脑转移发生率 4.2%。2022 年 12 月 8 日，eXalt 3 研究亚裔更新数据 在 MSK-CTONG 中美交流会上公布，在基线无脑转移人群中恩沙替尼组 PFS 达 47.1 个月，亚裔人群中盐酸恩沙替尼完全缓解率（CR 率）为 15.1%。2025 年 10 月，恩沙替尼术后辅助治疗数据在欧洲肿瘤内科学会（ESMO）年会上首次披露， 中期结果显示，恩沙替尼术后辅助治疗 2 年无病生存期（DFS）率达 86.4%，2 年 无病生存期风险比（HR）为 0.20，复发风险降低 80%，显著减少了疾病复 ...

Core Viewpoint - The recent acceptance notice from the National Medical Products Administration (NMPA) regarding the cancer drug "BPI-572270" has raised questions among investors about the relationship between Betta Pharmaceuticals Co., Ltd. and the lesser-known Hangzhou Jingyao Biotechnology Co., Ltd., which submitted the clinical trial application for the drug [1][6]. Group 1: Drug Development and Clinical Trials - "BPI-572270" targets challenging KRAS mutations, which are responsible for various cancers, with a mutation frequency of 20%-30% across all cancers [4]. - Betta Pharmaceuticals claims that "BPI-572270" is a potent pan-RAS inhibitor, showing strong cytotoxic effects against tumor cells with different KRAS, NRAS, and HRAS mutations, demonstrating nanomolar-level IC50 cell activity [4]. - The drug has shown tumor regression in mouse models of pancreatic cancer with low-dose oral administration and has favorable pharmacokinetic properties and safety profiles in animal studies [4]. Group 2: Company Structure and Strategy - Jingyao Biotechnology, established on October 17, 2025, has expanded its business scope to include drug production and wholesale, raising questions about its independence from Betta Pharmaceuticals [6]. - The proximity of Jingyao Biotechnology to Betta's incubation platform, "Betta Dream Factory," suggests a potential strategic relationship, reflecting a trend in the Chinese pharmaceutical industry towards platform and ecosystem models [6][9]. - Betta Pharmaceuticals positions itself as a platform-based pharmaceutical company, emphasizing its capabilities in drug discovery, commercialization, and innovative ecosystems [6][9].

格隆汇12月3日｜有投资者在互动平台向禾元生物提问：公司和国药控股的合作中，国药控股是作为合 同指定区域的独家代理，负责指定区域的药品销售，还是只是负责指定区域的药品配送，药品的销售推 广是由公司自己负责推销？这和贝达药业的合作模式是一样的吗？ 禾元生物回复称，公司已与国药控股、贝达药业等多家药品经销商签订经销协议，完成了全国30余个省 市区域的销售网络布局。国药控股是公司在特定区域的商业化合作伙伴。双方正在积极开展产品的学术 推广、市场拓展及渠道建设等相关工作，共同推动产品的市场覆盖和临床应用。 ...